Evidence map›Paper›PMID 32871842›Full record

ArticleIn vivo (Athens, Greece)

Stereotactic Body Radiotherapy for Pulmonary Oligometastasis from Colorectal Cancer.

Nao Kobayashi, Takanori Abe, Shin-Ei Noda, Y U Kumazaki, Ryuta Hirai, Mitsunobu Igari, Tomomi Aoshika, Satoshi Saito, Yasuhiro Ryuno, Shingo Kato

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Nao KobayashiDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Takanori AbeDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Shin-Ei NodaDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Y U KumazakiDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Ryuta HiraiDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Mitsunobu IgariDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Tomomi AoshikaDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Satoshi SaitoDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Yasuhiro RyunoDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan.
Shingo KatoDepartment of Radiation Oncology, Saitama Medical University, International Medical Center, Saitama, Japan s_kato@saitama-med.ac.jp.
Saitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimA retrospective study was conducted to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for pulmonary oligometastasis from colorectal cancer (CRC). PATIENTS AND

methodsPatients with pulmonary oligometastasis from CRC who were treated with SBRT between April 2010 and October 2018 were enrolled in this study. All patients underwent SBRT using Cyberknife® with a dose of 54-60 Gy in 3 fractions to 99% of the clinical target volume. The treatment efficacy was evaluated by the local control (LC) and overall survival (OS) rates. The toxicity was evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0.

resultsTwenty-six lesions in 20 patients were treated with SBRT. The median follow-up duration was 19 months (range=6-98 months). Local recurrence occurred in 6 of 26 lesions with a median follow-up of 12 months. The 2-year LC and OS rates were 65.8% and 88.6%, respectively. No patient developed ≥ grade 2 toxicity in the lung and other sites.

conclusionAlthough very high doses were delivered to the tumors with SBRT, the LC of pulmonary metastasis from CRC was not satisfactory when compared to that for stage I primary non-small cell lung cancer reported in the literature.

Indexed as

Carcinoma, Non-Small-Cell LungColorectal NeoplasmsLung NeoplasmsRadiosurgeryHumansLungNeoplasm Recurrence, LocalRetrospective StudiesTreatment Outcomecolorectal cancer (CRC)oligorecurrencepulmonary oligometastasisStereotactic body radiotherapy (SBRT)

Identifiers

PMID32871842
PMCPMC7652475
OpenAlexW3082144855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.